Warfarin Reversal in Intracranial Hemorrhage

Initial Management

For patients with intracranial hemorrhage on warfarin therapy, urgent reversal with 4-factor prothrombin complex concentrate (PCC) plus intravenous vitamin K 10 mg is strongly recommended as the first-line treatment, according to the American College of Critical Care Medicine 1, 2
Immediately discontinue warfarin when intracranial hemorrhage is present or suspected, as recommended by the Critical Care Medicine society 1, 3
Check INR level as soon as possible to guide reversal strategy, as suggested by the Critical Care Medicine guidelines 1
For patients with INR ≥ 1.4, administer vitamin K 10 mg IV along with PCC, according to the Critical Care Medicine recommendations 1, 2
Time is critical - implement rapid reversal protocols to ensure correction of coagulopathy within 4 hours of admission, as advised by the World Journal of Emergency Surgery 4

4-factor PCC (weight-based dosing according to INR) is preferred over 3-factor PCC due to more complete factor replacement, as recommended by the Critical Care Medicine society 1, 5
Vitamin K 10 mg IV (administered slowly over 20-30 minutes) is essential for durable reversal of anticoagulation and prevents INR rebound after initial correction, according to the Critical Care Medicine guidelines 1, 2
Fresh Frozen Plasma (FFP) 10-15 mL/kg IV may be used as an alternative when PCC is unavailable, but it is less effective and slower than PCC, as noted by the Critical Care Medicine and World Journal of Emergency Surgery societies 1, 2, 4

PCC administration is associated with improved outcomes in elderly patients with traumatic intracranial hemorrhage, as reported by the World Journal of Emergency Surgery 4

Recheck INR within 30-60 minutes after PCC administration to confirm adequate reversal, as recommended by the Critical Care Medicine society 1
Monitor for INR rebound within 24-48 hours, especially with shorter-acting reversal agents, according to the Critical Care Medicine guidelines 1
If INR remains elevated (≥1.4) after initial treatment, consider additional vitamin K 10 mg IV, as suggested by the Critical Care Medicine society 1

Recombinant activated factor VII (rFVIIa) is not recommended as first-line therapy due to thrombotic risk and lack of FDA approval for this indication, as advised by the World Journal of Emergency Surgery 5
Consider risks of thromboembolism when reversing anticoagulation (7.2-12% within 30 days), as reported by the World Journal of Emergency Surgery 4
Decision on when to restart anticoagulation should be carefully weighed against risk of thromboembolism (3-5% 30-day risk of ischemic stroke after discontinuation), according to the World Journal of Emergency Surgery 4

Delaying reversal while waiting for FFP preparation - time to correction is critical for preventing hematoma expansion, as noted by the World Journal of Emergency Surgery 4
Relying solely on vitamin K without concurrent PCC or FFP administration, as warned by the Critical Care Medicine and American College of Cardiology societies 1, 6
Using 3-factor PCC when 4-factor PCC is available (4-factor provides more complete factor replacement), as recommended by the Critical Care Medicine society 1
Failing to administer vitamin K concurrently with PCC/FFP, which can lead to INR rebound, as cautioned by the Critical Care Medicine society 1
Overlooking the need for follow-up INR monitoring to detect rebound coagulopathy, as emphasized by the Critical Care Medicine society 1